Survival Following Segmentectomy or Lobectomy in Patients With Stage IB Non-small-cell Lung Cancer

Bo Hao†, Lin Zhang†, Tao Fan*, Bohao Liu, Wenyang Jiang, Hao Hu and Qing Geng*

Department of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan, China

Background: Lobectomy with mediastinal lymph node dissection has always been recognized as the standardized treatment for early-stage non-small-cell lung cancer. However, the feasibility of segmentectomy performed in stage IB non-small-cell lung cancer (NSCLC) patients remains controversial. The present study aims to investigate whether the outcome of stage IB NSCLC patients undergoing segmentectomy was comparable to those who underwent lobectomy.

Method: We retrospectively collected data of 11,010 patients with primary stage IB non-small-cell lung cancer from the Surveillance, Epidemiology, and End Results database. Overall survival (OS) and lung cancer-specific survival (LCSS) were assessed among patients who were performed lobectomy or segmentectomy. To further assess the impact of the surgical procedures on patients with different tumor sizes, subgroups stratified by tumor size were analyzed.

Results: A total of 11,010 patients who were pathologically confirmed to be stage IB were included, of whom 10,453 received lobectomy and 557 received segmentectomy. Both univariate and multivariate Cox regression analyses showed that the patients receiving lobectomy had better OS [hazards ratio (HR) = 1.197, 95% confidence interval (CI) (1.066, 1.343), P < 0.001] than those receiving segmentectomy. However, multivariate analysis showed that there was no significant difference in LCSS between lobectomy and segmentectomy [HR = 1.172, 95% CI (0.963, 1.427), P = 0.114]. Meanwhile, subgroup analyses showed that lobectomy rather than segmentectomy was associated with better OS [HR = 1.278, 95% CI (1.075, 1.520) P = 0.006] and LCSS [HR = 1.118, 95% CI (1.005, 1.280), P = 0.047] for patients with a tumor size (TS) of ≤30 mm, while for patients with TS >30 mm, lobectomy yielded similar OS [TS ≤ 20 mm: HR = 1.068, 95% CI (0.853, 1.336), P = 0.566; TS > 20 and ≤30 mm: HR = 1.195, 95% CI (0.961, 1.487), P = 0.109] and LCSS [TS ≤ 20 mm: HR = 1.029, 95% CI (0.682, 1.552), P = 0.893; TS > 20 and ≤30 mm: HR = 1.144, 95% CI (0.795, 1.645), P = 0.469] to that of segmentectomy.

Conclusion: Segmentectomy achieved equivalent OS and LCSS in stage IB NSCLC patients with TS ≤ 30 mm compared with lobectomy. Lobectomy showed better OS and LCSS than segmentectomy for patients with a TS of >30 and ≤40 mm. Segmentectomy may be acceptable in patients with an older age and a smaller TS.

Keywords: non-small-cell lung cancer, segmentectomy, lobectomy, overall survival, lung cancer-specific survival
INTRODUCTION

Lung cancer has been the leading cause of cancer mortality worldwide, which makes lung cancer a major public health problem in the world (1). It is estimated that 234,030 cases were newly diagnosed and 154,050 died per year in the United States (2). According to the statistics, non-small-cell lung cancer (NSCLC) accounts for ~80% of all lung cancer cases (3). Thus, better treatment for NSCLC is urgently needed.

A study based on the Surveillance, Epidemiology, and End Results (SEER) database showed that NSCLC patients with a tumor size (TS) ≤1 cm, who underwent segmentectomy, had equivalent overall survival (OS) compared to those who had lobectomy (4). Later, an observational study using the same database demonstrated that lobectomy yielded better survival than segmentectomy in NSCLC patients with TS ≤ 2 cm who were diagnosed between 2000 and 2012 (5). Moon et al. (6) demonstrated that there were no significant differences in OS or lung cancer-specific survival (LCSS) among patients with TS ≤ 2 cm who underwent lobectomy vs. segmentectomy. Recently, a meta-analysis by Jsselidijk et al. (7) suggested that OS and disease-free survival (DFS) after segmentectomy yielded equivalent survival compared to lobectomy in NSCLC patients with stage T1aN0M0.

Thus, more and more studies suggest that segmentectomy yielded an equivalent survival rate compared to lobectomy in early-stage NSCLC patients. However, its survival comparison with lobectomy in stage IB non-small-cell lung cancer patients remains unknown. The present study aims to evaluate the impact of lobectomy and segmentectomy on OS and LCSS in stage IB (T2aN0M0) NSCLC patients using the SEER database.

METHODS

Data
Clinical information of all patients was obtained from the SEER database, which was supported by the National Cancer Institute. The database aims to collect and report the cancer incidence and survival data from several registries that involve more than 30% of the U.S. population and has been used for survival analyses in numerous high-quality studies (5, 8–12).

Study Population
The inclusion of the patients involved in the study include (1) NSCLC confirmed by pathology; (2) T2aN0M0 stage tumor based on the eighth edition of NSCLC stage classification (TS > 30 and ≤40 mm or TS ≤ 30 mm but involved with visceral pleural invasion); and (3) surgical history of lobectomy (surgery code: 20, and wedge resection was excluded) or segmentectomy (surgery code: 22, and wedge resection was excluded). And the exclusion criteria include (1) history of chemotherapy; (2) history of radiotherapy; (3) pathologically confirmed small cell lung cancer or all subtypes of sarcoma; (4) age < 18; (5) tumor located in the main bronchus, as a result of which segmentectomy was impossible to be performed.

The baseline characteristics of patients were obtained from the datasets: age, gender, race, year of diagnosis, location of tumor, laterality, pathology classification, the number of resected lymph nodes, TS, survival status, survival time, and cause of death. All eligible patients were divided into the segmentectomy group or lobectomy group according to the surgical strategies. History of malignancy was categorized as No (having no other malignancies before lung cancer diagnosis) and Yes (having one or more malignancies before lung cancer diagnosis). Grade well/moderate group included grade I and II, while poor/undifferentiated included III and IV.

The primary endpoint of this analysis was OS, which is calculated from the day of surgery to the last follow-up or death. The secondary endpoint was LCSS, calculated from the day of surgery to the day of NSCLC-related death or the date of the last follow-up.

Statistical Analysis
Conventional statistics were used to summarize the characteristics of the study. The Wilcoxon tests were used to calculate the distributions of continuous data (age, number of resected regional lymph nodes, and TS), and the Pearson χ² test was used in categorical variables (sex, location, laterality, pathology grade, and history of malignancy). Survival curves of OS and LCSS were calculated from the day of surgery to the day of NSCLC-related death or the date of the last follow-up.

RESULTS

Characteristics of the Study
A total of 11,010 NSCLC patients who were pathologically confirmed to be stage T2aN0M0 were included, of whom 10,453 underwent lobectomy and 557 segmentectomy. The year of diagnosis spanned from 2004 to 2013. The age of the cohort ranged from 22 to 94, and the average was 69. To further explore the impact of age on survival, the cohort was divided into three groups by age: ≤60, 61–75, and > 75. The median time and mean follow-up times of the entire cohort were 56 and 116.37 months, respectively. Baseline characteristics were depicted in Table 1. As shown in Table 1, segmentectomy is more likely to be performed in patients with an older age, White race, left lung lesions, advanced tumor grade, and a smaller TS. And a smaller number of lymph nodes were likely to be resected in patients who underwent segmentectomy.

Survival Analysis
The Kaplan–Meier survival analysis showed that lobectomy had better OS (P < 0.0001) and LCSS (P = 0.032) than segmentectomy (Figures 1, 2). And univariate and multivariate Cox regression analyses were further conducted. As shown in
TABLE 1 | Baseline characteristics of the study population.

|                      | Lobectomy (n = 10,453) | Segmentectomy (n = 557) | P-value |
|----------------------|-------------------------|-------------------------|---------|
| **Age**              |                         |                         | <0.001  |
| ≤60                  | 1,839 (17.6%)           | 63 (11.3%)              |         |
| 61–75                | 5,540 (53.0%)           | 282 (50.6%)             |         |
| >75                  | 3,074 (29.4%)           | 212 (38.1%)             |         |
| **Sex**              |                         |                         | 0.251   |
| Male                 | 5,084 (48.6%)           | 257 (46.1%)             |         |
| Female               | 5,369 (51.4%)           | 300 (53.9%)             |         |
| **Location**         |                         |                         | <0.001  |
| Upper                | 6,251 (58.9%)           | 336 (59.9%)             |         |
| Lower                | 3,359 (33.3%)           | 206 (37.4%)             |         |
| Others               | 843 (7.8%)              | 15 (2.7%)               |         |
| **Race**             |                         |                         | 0.805   |
| White                | 8,883 (85.3%)           | 479 (86.2%)             |         |
| Black                | 831 (8.0%)              | 41 (7.1%)               |         |
| Others               | 739 (6.7%)              | 37 (6.8%)               |         |
| **Pathology**        |                         |                         | 0.400   |
| Adenocarcinoma       | 6,539 (62.6%)           | 341 (61.2%)             |         |
| Squamous cell carcinoma | 2,704 (25.8%)       | 141 (25.3%)             |         |
| Others               | 1,210 (11.6%)           | 75 (13.5%)              |         |
| **Laterality**       |                         |                         | <0.001  |
| Left                 | 4,272 (40.9%)           | 313 (56.2%)             |         |
| Right                | 6,181 (59.1%)           | 244 (43.8%)             |         |
| **Grade**            |                         |                         | 0.004   |
| Well/moderate        | 6,310 (60.4%)           | 297 (53.3%)             |         |
| Poor/Undifferentiated| 3,560 (34.1%)           | 223 (40.0%)             |         |
| Unknown              | 583 (5.5%)              | 37 (6.8%)               |         |
| **No. of resected lymph nodes** |                 |                         | <0.001  |
| 0                    | 322 (3.1%)              | 139 (25.0%)             |         |
| 1–3                  | 1,716 (16.4%)           | 172 (30.9%)             |         |
| ≥4                   | 7,981 (75.9%)           | 214 (38.4%)             |         |
| Unknown              | 484 (4.6%)              | 32 (5.7%)               |         |
| **Tumor size (mm)** |                         |                         | <0.001  |
| ≤20                  | 2,230 (21.3%)           | 191 (34.3%)             |         |
| 21–30                | 2,564 (24.5%)           | 157 (28.2%)             |         |
| 31–40                | 5,659 (54.1%)           | 209 (37.5%)             |         |
| **History of malignancy** |                     |                         | <0.001  |
| No                   | 5,993 (57.3%)           | 256 (46.0%)             |         |
| Yes                  | 4,460 (42.7%)           | 301 (54.0%)             |         |

Tables 2, 3, univariate analyses suggested that an older age, male sex, White race, squamous cell carcinoma, advanced tumor grade, a smaller number of resected lymph nodes, and a larger TS yielded worse OS and LCSS. Patients undergoing segmentectomy had worse OS [HR = 1.442, 95% CI (1.295, 1.606), P < 0.001] and LCSS [HR = 1.224, 95% CI: (1.017, 1.473), P = 0.033]. In multivariate Cox regression, segmentectomy had poorer OS [HR = 1.197, 95% CI (1.066, 1.343), P = 0.002], but not poorer LCSS [HR = 1.172, 95% CI (0.963, 1.427), P = 0.114]. An older age, male sex, squamous cell carcinoma, advanced grade, and a smaller number of resected lymph nodes were associated with worse OS and LCSS. Interestingly, patients with a history of malignancy were associated with a better LCSS [HR = 0.311, 95% CI (0.280, 0.345), <0.001] compared with those without a history of malignancy; however, no significant difference was observed in OS [HR = 1.020, 95% CI (0.982, 1.075), P = 0.465].

Subgroup Analysis

To further explore the impact of TS on the choice of surgical strategy for stage IB NSCLC patients, subgroup analyses were conducted. As shown in Table 4, multivariate Cox regression analysis showed that segmentectomy yielded similar OS to that of lobectomy for NSCLC patients with TS ≤ 30 mm [TS ≤ 20 mm: HR = 1.068, 95% CI (0.853, 1.336), P = 0.566; TS > 20 and ≤30 mm: HR = 1.195, 95% CI (0.961, 1.487), P = 0.109], while in NSCLC patients with a TS of ≤40 and >30 mm, segmentectomy was associated with poorer OS [HR = 1.278, 95% CI (1.075, 1.520), P = 0.006]. We should note that in T2aN0M0 stage patients, if the size of tumor was ≤30 mm, the visceral pleural must have been invaded. As depicted in Table 5, segmentectomy achieved similar LCSS to that of lobectomy [TS ≤ 20 mm: HR = 1.029, 95% CI (0.682, 1.552), P = 0.893; TS > 20 and ≤30 mm, HR = 1.144, 95% CI (0.795, 1.645), P = 0.469]. However, segmentectomy yielded worse LCSS [HR = 1.118, 95% CI (1.005, 1.280), P = 0.047] in NSCLC patients with a TS of ≤40 and >30 mm.

DISCUSSION

Although lobectomy is recognized as the standard surgical treatment for patients with stage I NSCLC (13), the optimal surgical management of early-stage lung cancer still remains controversial. In recent years, with the development of surgical technological devices, surgical skills, and perioperative care, minimally invasive surgery has been increasingly accepted. More and more attention has been focused on sublobar resection as an alternative treatment for patients with early-stage NSCLC, especially the elderly ones and those with slight or moderate impairment of lung function. Moreover, patients who had undergone limited resection are more tolerant of reoperation if lung malignancies recur. In our study, we observed that lobectomy achieved better OS and LCSS than did segmentectomy; however, after being adjusted by other prognostic factors, no significant difference was observed in LCSS between them. To the best of our knowledge, this is the first study to compare the survival rates after lobectomy and segmentectomy for the eighth edition of stage IB NSCLC patients.

In 1995, a study by Ginsberg et al. (13) demonstrated that lobectomy should be recommended as the standard treatment for patients with peripheral T1N0 non-small-cell lung cancer. However, recent studies have tried to assess the difference in outcomes between lobectomy and sublobar resection. Wolf and his team members found that lobectomy was associated with longer OS and recurrence-free survival in NSCLC patients with TS ≤ 2 cm (14). However, other studies (6, 15–18) reported that segmentectomy was comparable to lobectomy in terms of OS for stage IA NSCLC. There was also evidence from several
studies of meta-analysis suggesting that segmentectomy could achieve comparable OS to lobectomy for stage IA NSCLC (19–21). It seemed that more and more studies suggested that segmentectomy could be the optimal surgical treatment for patients with stage IA NSCLC.

Numerous published studies explored the impact of segmentectomy and lobectomy on the prognosis of patients with stage IA or I NSCLC. It should be noted that stage I contains stages IA and IB. Most of previous studies of lung cancer were based on the seventh or sixth edition. T2N0M0 (T > 30 mm) was defined as stage IB in the sixth edition, and T2aN0M0 (T > 30 mm and T ≤ 50 mm) was defined as stage IB in the seventh. In 2012, Schuchert et al. (22) found that patients with stage IB NSCLC who underwent segmentectomy had reduced recurrence-free survival compared to those who underwent lobectomy. However, the TNM stage of the enrolled
patients was classified according to the sixth edition of the American Joint Committee on Cancer (AJCC) Lung Cancer Staging System, and the outcomes of stage IB NSCLC patients would probably be different because of tumor staging based on different editions. Recently, Zhang et al. (23) reported that sublobar resection achieved an equivalent outcome to that of lobectomy, and similar results were also observed in propensity-matched analysis. But we should note that patients who underwent segmentectomy and wedge resection were all included in their study as sublobar resection. Segmentectomy belongs to anatomical resection, while wedge resection does not. Whitson et al. (24) suggested that lobectomy confers a significant survival advantage over segmentectomy in stage I NSCLC patients. However, the tumor staging system was based on the sixth edition lung cancer stage classification of the AJCC. Both the sixth and seventh editions are different from the newest
TABLE 2 | Univariate and multivariate regression analyses for overall survival.

|                  | Univariate analysis | Multivariate analysis |
|------------------|---------------------|-----------------------|
|                  | HR                  | 95% CI                | P          | HR                  | 95% CI                | P          |
| **Age**          |                     |                       |           |                     |                       |           |
| ≤60              | 1                   |                       |           | 1                   |                       |           |
| 61–75            | 1.628               | 1.496–1.773           | < 0.001*  | 1.559               | 1.430–1.699           | < 0.001*  |
| >75              | 1.777               | 1.684–1.875           | < 0.001*  | 2.420               | 2.213–2.647           | < 0.001*  |
| **Sex**          |                     |                       |           |                     |                       |           |
| Male             | 1                   |                       |           | 1                   |                       |           |
| Female           | 0.703               | 0.667–0.740           | < 0.001*  | 0.707               | 0.669–0.746           | < 0.001*  |
| **Race**         |                     |                       |           |                     |                       |           |
| White            | 1                   |                       |           | 1                   |                       |           |
| Black            | 0.856               | 0.773–0.947           | 0.003*    | 0.929               | 0.838–1.029           | 0.159     |
| Others           | 0.771               | 0.690–0.861           | < 0.001*  | 0.845               | 0.756–0.945           | 0.001*    |
| **Laterality**   |                     |                       |           |                     |                       |           |
| Left             | 1                   |                       |           | 1                   |                       |           |
| Right            | 0.991               | 0.941–1.045           | 0.748     | 1.038               | 0.983–1.096           | 0.179     |
| **Location**     |                     |                       |           |                     |                       |           |
| Upper            | 1                   |                       |           | 1                   |                       |           |
| Lower            | 1.097               | 1.037–1.160           | 0.001*    | 1.067               | 1.008–1.128           | 0.025*    |
| Others           | 0.978               | 0.884–1.083           | 0.673     | 0.966               | 0.861–1.062           | 0.402     |
| **Pathology**    |                     |                       |           |                     |                       |           |
| Adenocarcinoma   | 1                   |                       |           | 1                   |                       |           |
| Squamous cell carcinoma | 1.563   | 1.475–1.656           | < 0.001*  | 1.331               | 1.252–1.415           | < 0.001*  |
| Others           | 1.273               | 1.174–1.381           | < 0.001*  | 1.168               | 1.074–1.270           | < 0.001*  |
| **Grade**        |                     |                       |           |                     |                       |           |
| Well/Moderate    | 1                   |                       |           | 1                   |                       |           |
| Poor/Undifferentiated | 1.277   | 1.210–1.348           | < 0.001*  | 1.177               | 1.112–1.246           | < 0.001*  |
| Unknown          | 0.846               | 0.748–0.956           | 0.007*    | 0.863               | 0.763–0.977           | 0.012*    |
| **Resected lymph nodes** |       |                       |           |                     |                       |           |
| 0                | 1                   |                       |           | 1                   |                       |           |
| 1–3              | 0.754               | 0.666–0.854           | < 0.001*  | 0.775               | 0.682–0.882           | < 0.001*  |
| ≥4               | 0.597               | 0.532–0.669           | < 0.001*  | 0.625               | 0.554–0.705           | < 0.001*  |
| Unknown          | 0.645               | 0.549–0.757           | < 0.001*  | 0.680               | 0.577–0.802           | < 0.001*  |
| **Tumor size (mm)** |                 |                       |           |                     |                       |           |
| ≤20              | 1                   |                       |           | 1                   |                       |           |
| 21–30            | 1.272               | 1.176–1.376           | < 0.001*  | 1.180               | 1.090–1.276           | < 0.001*  |
| 31–40            | 1.314               | 1.227–1.407           | < 0.001*  | 1.159               | 1.081–1.243           | < 0.001*  |
| **History of malignancy** |       |                       |           |                     |                       |           |
| No               | 1                   |                       |           | 1                   |                       |           |
| Yes              | 1.126               | 1.069–1.186           | < 0.001*  | 1.020               | 0.968–1.075           | 0.465     |
| **Surgical procedure** |           |                       |           |                     |                       |           |
| Lobectomy        | 1                   |                       |           | 1                   |                       |           |
| Segmentectomy    | 1.442               | 1.295–1.606           | < 0.001*  | 1.197               | 1.086–1.343           | 0.002*    |

*indicates that the difference was statistically significant.
TABLE 3 | Univariate and multivariate regression analyses for lung cancer specific survival.

|                | Univariate analysis | Multivariate analysis |
|----------------|---------------------|-----------------------|
|                | HR  | 95%CI     | P       | HR  | 95%CI     | P       |
| **Age**        |     |           |         |     |           |         |
| ≤60            | 1   |           |         | 1   |           |         |
| 61–75          | 1.243 | 1.103–1.402 | < 0.001* | 1.394 | 1.234–1.574 | < 0.001* |
| >75            | 1.482 | 1.302–1.687 | < 0.001* | 1.669 | 1.482–1.905 | < 0.001* |
| **Sex**        |     |           |         |     |           |         |
| Male           | 1   |           |         | 1   |           |         |
| Female         | 0.787 | 0.724–0.856 | < 0.001* | 0.768 | 0.703–0.838 | < 0.001* |
| **Race**       |     |           |         |     |           |         |
| White          | 1   |           |         | 1   |           |         |
| Black          | 0.835 | 0.707–0.986 | 0.034* | 0.847 | 0.716–1.003 | 0.054 |
| Others         | 1.054 | 0.901–1.232 | 0.513 | 0.989 | 0.846–1.158 | 0.896 |
| **Laterality** |     |           |         |     |           |         |
| Left           | 1.060 | 0.973–1.154 | 0.181 | 1.099 | 1.007–1.199 | 0.035* |
| Right          |     |           |         |     |           |         |
| **Location**   |     |           |         |     |           |         |
| Upper          | 1   |           |         | 1   |           |         |
| Lower          | 1.050 | 0.969–1.149 | 0.290 | 1.064 | 0.972–1.166 | 0.180 |
| Others         | 0.919 | 0.778–1.085 | 0.318 | 0.911 | 0.768–1.081 | 0.287 |
| **Pathology**  |     |           |         |     |           |         |
| Adenocarcinoma | 1   |           |         | 1   |           |         |
| Squamous cell carcinoma | 1.407 | 1.279–1.548 | < 0.001* | 1.222 | 1.105–1.351 | < 0.001* |
| Others         | 1.361 | 1.200–1.544 | < 0.001* | 1.213 | 1.064–1.382 | 0.004* |
| **Grade**      |     |           |         |     |           |         |
| Well/Moderate  | 1   |           |         | 1   |           |         |
| Poor/Undifferentiated | 1.347 | 1.235–1.469 | < 0.001* | 1.255 | 1.146–1.374 | < 0.001* |
| Unknown        | 0.807 | 0.667–0.990 | 0.040* | 0.801 | 0.651–0.985 | 0.036* |
| **No. of resected lymph nodes** |     |           |         |     |           |         |
| 0              | 1   |           |         | 1   |           |         |
| 1–3            | 0.841 | 0.685–1.034 | 0.100 | 0.785 | 0.635–0.970 | 0.025* |
| ≥4             | 0.645 | 0.533–0.780 | < 0.001* | 0.587 | 0.481–0.717 | < 0.001* |
| Unknown        | 0.706 | 0.543–0.919 | 0.009* | 0.654 | 0.500–0.855 | 0.002* |
| **Tumor size (mm)** |     |           |         |     |           |         |
| ≤20            | 1   |           |         | 1   |           |         |
| 21–30          | 1.398 | 1.230–1.589 | < 0.001* | 1.316 | 1.157–1.496 | < 0.001* |
| 31–40          | 1.432 | 1.279–1.603 | < 0.001* | 1.310 | 1.167–1.470 | < 0.001* |
| **History of malignancy** |     |           |         |     |           |         |
| No             | 1   |           |         | 1   |           |         |
| Yes            | 0.332 | 0.299–0.368 | < 0.001* | 0.311 | 0.280–0.345 | < 0.001* |
| **Surgical procedure** |     |           |         |     |           |         |
| Lobectomy      | 1   |           |         | 1   |           |         |
| Segmentectomy  | 1.224 | 1.017–1.473 | 0.033* | 1.172 | 0.963–1.427 | 0.114 |

*indicates that the difference was statistically significant.

performed to remove the bias. The multivariate analyses showed that an older age, male sex, squamous cell carcinoma, advanced grade, a smaller numbers of resected lymph nodes, and a larger TS were independent prognostic factors, and they predicted worse OS and LCSS. Interestingly, patients with a history of malignancy had longer LCSS and seemed to have worse OS. However, the difference in OS was not significant between patients with such a history and those without. We speculated that the reason may be that patients with other malignancies were more likely to die of other recurrent cancers or long-term post-operative complications.

A previous study reported that mediastinal lymph node metastasis was significantly associated with poorer tumor differentiation degree, and a larger number of positive
lymph nodes were significantly associated with worse OS and progression-free survival (26). Cao et al. (27) found that the more extensive the regional lymph node dissection was, the better the survival of patients who undergo sublobar resection for stage IA NSCLC with TS ≤ 2 cm. Our study also strongly demonstrated that a larger number of regional lymph nodes with dissection were associated with better LCSS and OS in stage IB patients. We speculated that the smaller the number of resected lymph nodes, the more likely the potential positive lymph nodes were unremoved. The potential unremoved positive lymph nodes may lead to the recurrence of lung cancer or distant metastasis after operation. Therefore, a thoracic surgeon should attach enough importance to the enlarged lymph nodes on CT/PET-CT before operation and remove the visible regional lymph nodes as much as possible.

In subgroups, multivariate analyses showed that segmentectomy yielded similar OS and LCSS for NSCLC patients with TS ≤ 30 mm compared with lobectomy. However, segmentectomy yielded worse OS and LCSS for NSCLC patients with TS > 30 mm and T ≤ 40 mm. We acknowledged that segmentectomy was likely to be performed in older patients who had a smaller TS, especially in those with an impaired lung function. In addition, more regional lymph nodes were likely to be resected when lobectomy was performed compared to segmentectomy. As discussed in the previous paragraph, the more the regional lymph nodes were resected, the better the outcome the patients would have. Taking the above factors into consideration, segmentectomy may be acceptable for appropriately selected stage IB NSCLC patients with an older age and a smaller TS, especially for those with comorbidities. However, the conclusion needs to be validated by multicenter randomized controlled trials (RCTs).

Previous studies reported that segmentectomy was associated with less blood loss, shorter operation time, shorter chest...
REFERENCES

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. (2015) 65:87–108. doi: 10.3322/caac.21262.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. (2018) 68:7–30. doi: 10.3322/caac.21442.
3. Travis WD. Pathology of lung cancer. Clin Chest Med. (2011) 32:669–92. doi: 10.1016/j.ccm.2011.08.005.
4. Kates M, Swanson S, Wisnivesky JP. Survival following lobectomy and limited resection for the treatment of stage I non-small cell lung cancer (<1 cm in size: a review of SEER data. Chest. (2011) 139:491–6. doi: 10.1378/chest.09-2547.
5. Dai CY, Shen JF, Ren YJ, Zhong SY, Zheng H, He YX, et al. Choice of surgical procedure for patients with non-small-cell lung cancer (=1 cm or > 1 to 2 cm among lobectomy, segmentectomy, and wedge resection: a population-based study. J Clin Oncol. (2016) 34:3175–82. doi: 10.1200/JCO.2015.64.6729.
6. Moon MH, Moon YK, Moon SW. Segmentectomy versus lobectomy in early non-small cell lung cancer of 2 cm or less in size: a population-based study. Respirology. (2018) 23:695–703. doi: 10.1111/resp.13277.
7. Ijjiseldijk MA, Shoni M, Siegert C, Seegers J, van Engelenburg AKC, Tsi TC, et al. Oncological outcomes of lobar resection, segmentectomy and wedge resection for T1a non- small cell lung carcinoma: a systematic review and meta-analysis. Semin Thorac Cardiovasc Surg. (2019). doi: 10.1053/j.semtcvs.2019.08.004. [Epub ahead of print].
8. Liu Y, Shan L, Shen J, Liu L, Wang J, He J, et al. Choice of surgical procedure - lobectomy, segmentectomy, or wedge resection - for patients with stage T1-2N0M0 small cell lung cancer: a population-based study. Thorac cancer. (2019) 10:593–600. doi: 10.1111/1759-7714.12943.
9. Soneji S, Tanner NT, Silvestri GA, Lathan CS, Black W. Racial and ethnic disparities in early-stage lung cancer survival. Chest. (2017) 152:587–97. doi: 10.1016/j.chest.2017.03.059.
10. Yoon JY, Siegel K, Martin J, Jordan R, Beasley MB, Smith C, et al. Evaluation of the prognostic significance of TNM staging guidelines in lung carcinoid tumors. J Thorac Oncol. (2019) 14:184–92. doi: 10.1016/j.jtho.2018.10.166.
11. Thakur MK, Ruteterbusch JJ, Schwartz AG, Gadgeel SM, Beebe-Dimmer JL, Wozniak AJ. Risk of second lung cancer in patients with previously treated lung cancer: analysis of surveillance, epidemiology, and end results (SEER) data. J Thorac Oncol. (2018) 13:46–53. doi: 10.1016/j.jtho.2017.09.1964.
12. Zhao M, Lu T, Huang Y, Yin J, Jiang T, Li M, et al. Survival and long-term cause-specific mortality associated with stage IA lung adenocarcinoma after wedge resection vs. segmentectomy: a population-based propensity score matching and competing risk analysis. Front Oncol. (2019) 9:593. doi: 10.3389/fonc.2019.00593.
13. Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung cancer study group. Ann Thorac Surg. (1995) 60:615–22; discussion 622–3. doi: 10.1016/0003-4975(95)00537-U.
14. Wolf AS, Richards WG, Jaklitsch MT, Gill R, Chirieac LR, Colson YL, et al. Lobectomy versus sublobar resection for small (2 cm or less) non- small cell lung cancers. Ann Thorac Surg. (2011) 92:1819–23; discussion 1824–5. doi: 10.1016/j.athoracsur.2011.06.099.
15. Wisnivesky JP, Henschke CI, Swanson S, Yankelevitz DF, Zulueta J, Marcus S, et al. Limited resection for the treatment of patients with stage IA lung cancer. Ann Surg. (2010) 251:550–4. doi: 10.1097/SLA.0b013e3181ce5f3.
16. Yendamuri S, Sharma R, Demmy M, Groman A, Hennon M, Dexter E, et al. Temporal trends in outcomes following sublobar and lobare resections for small (<= 2 cm) non-small cell lung cancers—a surveillance...
17. Zhong C, Fang W, Mao T, Yao F, Chen W, Hu D. Comparison of thoracoscopic segmentectomy and thoracoscopic lobectomy for small-sized stage IA lung cancer. Ann Thorac Surg. (2012) 94:362–7. doi: 10.1016/j.athoracsur.2012.04.047

18. Gu C, Wang R, Pan X, Huang Q, Zhang Y, Yang J, et al. Sublobar resection versus lobectomy in patients aged <35 years with stage IA non-small cell lung cancer: a SEER database analysis. J Cancer Res Clin Oncol. (2017) 143:2375–82. doi: 10.1007/s00432-017-2499-y

19. Zhang L, Li M, Yin R, Zhang Q, Xu L. Comparison of the oncologic outcomes of anatomic segmentectomy and lobectomy for early-stage non-small cell lung cancer. Ann Thorac Surg. (2015) 99:728–37. doi: 10.1016/j.athoracsur.2014.08.080

20. Fan J, Wang L, Jiang GN, Gao W. Sublobectomy versus lobectomy for stage I non-small-cell lung cancer, a meta-analysis of published studies. Ann Surg Oncol. (2012) 19:661–8. doi: 10.1245/s10434-011-1931-9

21. Tao F, Ye P, Yang Y, Wang L, Zhang C, Lv X, et al. Segmentectomy or lobectomy for early stage lung cancer: a meta-analysis. Eur J Cardiothorac Surg. (2014) 46:1–7. doi: 10.1093/ejcts/ezt554

22. Schuchert MJ, Awais O, Abbas G, Horne ZD, Nason KS, Pennathur A, et al. Influence of age and IB status after resection of node-negative non-small cell lung cancer. Ann Thorac Surg. (2012) 93:929–35; discussion 935–6. doi: 10.1016/j.athoracsur.2011.09.047

23. Zhang Z, Feng H, Zhao H, Hu J, Liu L, Liu Y, et al. Sublobar resection is associated with better perioperative outcomes in elderly patients with clinical stage I non-small cell lung cancer: a multicenter retrospective cohort study. J Thorac Dis. (2019) 11:1838–48. doi: 10.21037/jtd.2019.05.20

24. Whitson BA, Groth SS, Andreade RS, Maddaus MA, Habermann EB, D’Cunha J. Survival after lobectomy versus segmentectomy for stage I non-small cell lung cancer: a population-based analysis. Ann Thorac Surg. (2011) 92:1943–50. doi: 10.1016/j.athoracsur.2011.05.091

25. Deterbeck FC, Boffa DJ, Kim AW, Tanoue LT. The eighth edition lung cancer stage classification. Chest. (2017) 151:193–203. doi: 10.1016/j.chest.2016.10.010

26. Xiong J, Wang R, Sun Y, Chen H. Clinical analysis of sixty-four patients with T1aN2M0 stage non-small cell lung cancer who had undergone resection. Thorac cancer. (2016) 7:215–21. doi: 10.1111/1759-7714.12314

27. Cao J, Xu J, He Z, Yuan P, Huang S, Lv W, et al. Prognostic impact of lymphadenectomy on outcomes of sublobar resection for stage IA non-small cell lung cancer <2 cm. J Thorac Cardiovasc Surg. (2018) 156:796–805.e4. doi: 10.1016/j.jtcvs.2018.03.122

28. Liu C, Wang G, Xu J, Cui L, Dong W, Ni Y, et al. Sublobectomy versus lobectomy for stage I non-small cell lung cancer in the elderly. Int J Surg. (2017) 37:1–7. doi: 10.1016/j.ijsu.2016.11.090

29. Handa Y, Tsutani Y, Mimae T, Miyata Y, Okada M. Complex segmentectomy in the treatment of stage IA non-small-cell lung cancer. Eur J Cardiothorac Surg. (2019) 57:114–21. doi:10.1093/ejcts/ezz185

30. Okami J, Ito Y, Higashiyama M, Nakayama T, Tokunaga T, Maeda J, et al. Sublobar resection provides an equivalent survival after lobectomy in elderly patients with early lung cancer. Ann Thorac Surg. (2010) 90:1651–6. doi: 10.1016/j.athoracsur.2010.06.090

31. Suzuki K, Saji H, Aokage K, Watanabe SI, Okada M, Mizusawa J, et al. Comparison of pulmonary segmentectomy and lobectomy: safety results of a randomized trial. J Thorac Cardiovasc Surg. (2019) 158:895–907. doi: 10.1016/j.jtcvs.2019.03.090

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.